Background

Precision medicine, which comprehensively analyzes the genetic and molecular characteristics of individual patients to identify the optimal treatment, is rapidly advancing. Multi-omics technology, which integrates and analyzes various molecular layer information such as genomics, transcriptomics, proteomics, and metabolomics, is considered a key tool for elucidating diseases in a comprehensive manner. Recently, as analytical technology has matured, data analysis costs have also decreased significantly compared to the past.

However, despite academic achievements, there are still high barriers to entry in the actual clinical application of multi-omics. The current hospital diagnostic system is built to confirm fragmented numerical values, such as single-gene tests. It is almost impossible for individual medical institutions to standardize and interpret large-scale multi-molecular data with their existing infrastructure alone. This is why specific guidelines are needed to move beyond the data generation stage and apply it to actual patient care.

Key Findings

This Perspective article, published in the international journal Nature Genetics, presents a concrete roadmap to resolve the bottlenecks that hinder the clinical application of multi-omics technology. The researchers appear to have focused on formalizing solutions in four key areas – pre-analytical, computational, regulatory, and ethical – based on the operational experience of global precision medicine projects, including the Qatar Precision Health Institute (QPHI). The core idea is to precisely control the probabilistic variables that occur in the process of combining multi-dimensional data. Ensuring reliability is key.

In particular, the importance of Explainable AI (XAI) in the process of integrating analytical data is emphasized. In order to gain trust in the clinical setting, regulatory agencies and clinicians must be able to transparently verify how complex multi-omics analysis results are derived. The researchers established detailed measures in each field to increase data reliability.

First, in the pre-analytical stage, sample collection and storage processes should be standardized to minimize distortion of molecular data. Second, in the data calculation stage, a standard algorithm that integrates heterogeneous data without bias should be applied. Third, regulatory agencies should establish new guidelines optimized for multi-dimensional probabilistic models, rather than the existing approval system centered on single variables. Finally, in the ethical area, it is suggested that the criteria for sharing incidental findings and measures to protect personal identity should be clearly defined.

Significance and Prospects

This research is expected to be a turning point in which multi-omics moves beyond the laboratory level and is organically integrated with the actual healthcare system. A decrease in analysis costs does not immediately guarantee the popularization of precision medicine. Therefore, improvements to the entire healthcare system must accompany this. In addition, it is urgent to establish an education system that introduces multidisciplinary care models to help medical staff correctly interpret complex probabilistic data and explain it to patients.

Securing interoperability between national-level large-scale bio-data platforms is also a factor that will determine the success of the future precision medicine market. If standardization is lacking, there is a risk of producing healthcare services that are biased towards specific races or countries. In order for multi-omics diagnostic technology to be commercialized, the establishment of flexible approval systems by regulatory authorities and the introduction of health insurance coverage should be established as soon as possible.